Jenphar Bangladesh Limited (JBL), a subsidiary of Radiant Pharmaceuticals Ltd., has established itself as a prominent presence in the pharmaceutical industry. Jenphar has its legacy from Julphar Bangladesh Ltd, as a subsidiary of Julphar UAE, one of the largest pharmaceutical manufacturers in the Middle East and Africa. In a strategic move to expand its life-saving drug business, Radiant assimilated Julphar Bangladesh Ltd into Radiant Business Consortium Ltd on July 13, 2020, and subsequently renamed it Jenphar Bangladesh Ltd on Sept 29, 2021. The state-of-the-art manufacturing facilities of JBL has been engineered to comply international regulatory requirements like WHO-GMP, US-FDA & Australian-TGA guidelines. Its product portfolio encompasses over 100 registered products, including Antibiotics, Anti-ulcerants, Pain killers, Anti-hypertensive, Anti-diabetics, Anti-asthmatic, Dermatological and Nutritional supplements. Spanning across 5.4 acres of landscaped, the manufacturing plant combines cutting-edge technology with the natural aesthetic beauty of its environment. JBL has embarked on an ambitious journey of expansion with various strategic projects in the pipeline, including dedicated Oncology facility, Soft gelatin capsules and Cephalosporin injections. Within its two years of operation, Jenphar has gained recognition for delivering products of the highest standard, particularly in the treatment of Cancer, Liver diseases, and Thalassemia. The Government of Bangladesh has also acknowledged its efforts by awarding prestigious export incentives. Leveraging the extensive distribution network of Radiant Distributions Ltd, JBL ensures broader market reach to patients. Moreover, it benefits from the expertise of the Radiant Centre for Professionals, allowing JBL to quickly cultivate a highly competent workforce. With its unwavering commitment to innovation and the strong backing of Radiant, JBL is set to engrave its bold footprint in the healthcare sector.